AbbVie acquires Apogee Therapeutics for $10.9 billion (opens in new tab)
The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis
Read the original articleThe all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis
Read the original article